Skip to main content

Table 6 Univariate and multivariate logistic regression analyses for classification of prostate tumor vs normal prostate based on probe methylation

From: Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression

Gene

Probe

Univariate p value

Univariate odds ratio

95% confidence interval

Multivariate p value

Multivariate odds ratio

95% confidence interval

ASB2

cg01956154

3.48E−05***

0.3

0.17–0.53

0.72

1.46

0.18–11.84

ASB2

cg19949550

5.37E−11***

0.18

0.11–0.30

0.09

0.3

0.070–1.20

ASB2

cg09247392

4.42E−07***

0.09

0.04–0.24

0.18

0.12

0.010–2.60

ETNK2

cg20136584

4.89E−09***

16.64

6.49–42.68

**0.0014

154.88

6.95–3449.78

ETNK2

cg21535580

6.27E−05***

3.17

1.80–5.59

0.08

19.76

0.70–559.54

ETNK2

cg00103329

1.09E−08***

8.27

4.01–17.07

0.26

11.95

0.15–933.7

ETNK2

cg01566404

1.38E−08***

5.69

3.12–10.36

0.17

0.09

0.00–2.78

MEIS2

cg01958086

1.12E−14***

2.85

2.19–3.72

0.73

0.81

0.24–2.70

MEIS2

cg03951374

< 2.00E−16***

3.88

2.84–5.29

0.77

0.81

0.20–3.33

MEIS2

cg13800209

2.08E−12***

2.57

1.97–3.34

0.064

1.88

0.96–3.66

MEIS2

cg07433663

< 2.00E−16***

2.35

1.92–2.88

0.46

0.75

0.35–1.60

MEIS2

cg21643314

8.79E−13***

3.77

2.62–5.43

0.71

0.79

0.23–2.72

NRG1

cg04773818

3.41E−14***

2.08

1.72–2.52

0.67

0.85

0.40–1.80

NRG1

cg04555373

3.96E−14***

3.18

2.35–4.28

0.071

4.67

0.88–24.94

NRG1

cg03430846

2.84E−14***

3.5

2.54–4.84

0.31

0.44

0.090–2.11

NRG1

cg24946597

2.41E−11***

2.82

2.08–3.83

0.81

0.9

0.37–2.16

NRG1

cg00614182

1.16E−13***

3.76

2.65–5.34

*0.049

2.7

1.70–26.00

NTN1

cg14615768

< 2.00E−16***

6.12

4.03–9.27

0.46

0.53

0.10–2.83

NTN1

cg17072465

0.000213***

3.25

1.74–6.08

0.36

0.32

0.030–3.71

NUDT10

cg21844331

0.14

1.37

0.90–2.09

NA

NA

NA

NUDT10

cg22363867

4.44E−07***

3.28

2.07–5.21

0.3

0.37

0.060–2.41

NUDT10

cg15159291

0.02*

2.82

1.18–6.78

0.35

0.18

0.00–6.51

NUDT10

cg00648125

4.38E−05***

2.94

1.75–4.93

0.9

0.91

0.21–3.98

NUDT10

cg02975846

2.53E−05***

2.7

1.70–4.29

0.19

3.84

0.52–28.62

NUDT10

cg20430749

0.023*

1.51

1.06–2.15

0.23

0.32

0.050–2.05

NUDT10

cg06481089

0.13

0.65

0.37–1.13

NA

NA

NA

NUDT10

cg09520583

6.25E−06***

6.47

2.88–14.55

0.2

2.72

0.58–12.76

SRPX

cg16626088

2.13E−08***

26.69

8.46–84.23

0.99

1.01

0.090–11.53

SRPX

cg14759284

4.31E−13***

6

3.70–9.74

0.98

0.99

0.30–3.24

SRPX

cg19736094

6.00E−13***

5.11

3.44–7.58

0.57

0.62

0.12–3.14

SRPX

cg17407511

< 2.00E−16***

4.82

3.36–6.91

0.38

2.11

0.39–11.28

SRPX

cg27485646

1.03E−11***

6.98

3.99–12.23

0.56

0.66

0.16–2.66

SRPX

cg03509565

8.40E−13**

8.04

4.54–14.23

0.073

5.25

0.85–32.27

  1. Odds ratios and p values presented for methylation M values (logistic-transformed beta values)
  2. Statistical significance indicated by asterisks: *0.01 < p < 0.05; ***p < 0.001
Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us